Vivimed Labs Ltd

Upcoming CoC meeting

• Sixth CoC meeting for Vivimed Labs under CIRP on 18 Aug 2026 via audio-visual means.
• Pre-Facto intimation under CIRP Regulations for the upcoming meeting.
• Previous meetings: Third on 18-06-2026; Fourth on 04-07-2026; Fifth on 20-07-2026.
• Notice date: 17 Aug 2026.
• Interim Resolution Professional: Narayana Swamy.

Results & CIRP status

• Board approved audited standalone and consolidated results for year ended 31 Mar 2026.
• Auditors SVRL & Co issued qualified opinions on standalone and consolidated results.
• Going concern uncertainties noted; management plans restructuring; opinion not modified.
• CIRP admitted by NCLT; IRP appointed; CoC meeting held on 13 May 2026.
• Board powers suspended; IRP to manage operations during CIRP.
• SBI debt assigned to ARC; liability remains as borrowings.
• One Time Settlement with lenders; upfront payment made; impact to be recognized later.
• Inventory write-down of Rs 233.08 million primarily due to WIP.
• Standalone cash flow from operations Rs 44.47 million; year-end cash Rs 0.69 million.
• Consolidated cash flow from operations Rs 77.03 million; year-end cash Rs 13.56 million.
• Auditors flag unrecorded interest expense of Rs 625.72 million.
• MSME disclosures pending; confirmations outstanding.
• CBI investigation noted; potential impact not determined.
• CIRP outcome not ascertainable; CIRP ongoing.

Business context

• Pharma-focused company; primary Pharma segment.
• Group includes Vivimed Pharma Mauritius and Vivimed USA.
• CIRP initiated on Apr 15, 2026; IRP appointed; CoC meeting on May 13, 2026.

Audit observations & disclosures

• Qualified opinion; unrecorded interest expense Rs 625.72 million.
• MSME disclosures pending; vendor confirmations outstanding.
• CBI investigation noted; potential impact not determined.
• Land advances Rs 372.69 million; recoverability uncertain.
• Inventory write-down of Rs 233.08 million due to WIP.

Meeting Details

• Date: 17 July 2026; Time: not disclosed; Location: Hyderabad.

Key Agenda Items

• Consider and approve Audited Financial Results (Standalone & Consolidated) for quarter and year ended 31 March 2026.

Dematerialisation status

• RTA confirms compliance under Regulation 74(5) for 01/04/2026 to 30/06/2026.
• Dematerialised securities are listed on the exchanges where the earlier issues are listed.
• Physical certificates forwarded for dematerialisation were mutilated and cancelled after verification.
• Depository name substituted as registered owner in the records.
• Actions completed within 15 days of receipt of certificates from depository participants.

Vivimed Labs Limited trading window closure from 01.07.2026 till 48 hours after the declaration of the Financial Results of the Company for the quarter ended June 30, 2026 which becomes generally available information.

Meeting Details

• Board meeting scheduled for Thursday, 28 May 2026, at Hyderabad.

Key Agenda Items

• Approve audited standalone and consolidated financial results for quarter and year ended 31 March 2026.

Other Notes

• No additional material items were disclosed in this notice.